E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Deficiency of LRP8 in mice is associated with altered platelet function and prolonged time for in vivo thrombosis
Jason O. Robertson,Wei Li,Roy L. Silverstein,Roy L. Silverstein,Eric J. Topol,Jonathan D. Smith,Jonathan D. Smith +6 more
TL;DR: The results suggest that LRP8 is capable of altering thrombosis without affecting normal hemostasis through mechanisms both dependent on and independent of apoE, and suggests a means whereby clot formation could be affected in humans with L RP8 gene variants.
Journal ArticleDOI
The impact of fibrinolytic therapy for ST-segment-elevation acute myocardial infarction.
TL;DR: The history of fibrinolytic therapy and of tissue‐plasminogen activator (t‐PA) more particularly and the current indications for its use in the era of mechanical reperfusion are reviewed.
Journal ArticleDOI
Reactivation of Ischemic Events in Acute Coronary Syndromes: Results From GUSTO-IIb
Maria Cecilia Bahit,Eric J. Topol,Robert M. Califf,Paul W. Armstrong,Douglas A. Criger,Vic Hasselblad,Amadeo Betriu,Jack Hirsh,Diego Ardissino,Christopher B. Granger +9 more
TL;DR: The incidence of (re)MI was clustered within 12 h of heparin therapy discontinuation, with the greatest risk within 4 h, and there was no evidence of early reactivation of thrombotic events after hirudin.
Journal ArticleDOI
Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction : a quantitative angiographic and hematologic study
Jeffrey J. Popma,Robert M. Califf,Stephen G. Ellis,Barry S. George,Dean J. Kereiakes,Joseph Samaha,Seth J. Worley,Jeffrey L. Anderson,David C. Stump,Lynn H. Woodlief,Kristina N. Sigmon,Thomas C. Wall,Eric J. Topol +12 more
TL;DR: Lower in-hospital clinical event and reocclusion rates observed with combination thrombolytic therapy may relate to systemic hematologic factors rather than to the residual lumen obstruction after thromBOlysis.
Journal ArticleDOI
Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition. results from the TARGET trial
Mitchell J. Ross,Howard C. Herrmann,David J. Moliterno,James C. Blankenship,Laura A. Demopoulos,Peter M. DiBattiste,Stephen G. Ellis,Ziyad M.B. Ghazzal,Jack L. Martin,Jennifer White,Eric J. Topol +10 more
TL;DR: In this paper, the authors sought to assess whether pre-procedural angiographic characteristics are associated with adverse clinical outcomes after coronary stenting with glycoprotein IIb/IIIa inhibition.